temozolomide has been researched along with casein kinase ii in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aujla, PS; Bolin, S; Cho, YJ; Li, G; Luo, E; Nitta, RT; Nwagbo, G; Purzner, T; Samghabadi, P; Solow-Codero, DE | 1 |
| Arús, C; Candiota, AP; Martínez-Escardó, L; Villamañan, L; Yuste, VJ | 1 |
2 other study(ies) available for temozolomide and casein kinase ii
| Article | Year |
|---|---|
Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Casein Kinase II; Enzyme Inhibitors; Humans; Medulloblastoma; Prognosis; Temozolomide | 2019 |
Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calreticulin; Casein Kinase II; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Glioblastoma; Humans; Inflammation; Microscopy, Fluorescence; Naphthyridines; Phenazines; Propidium; Signal Transduction; Temozolomide; Treatment Outcome | 2021 |